Compare Novo Nordisk A/S (NVO) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs United States Natural Gas Fund — how do they compare? Novo Nordisk A/S trades at $38.45 (market cap $165.31B), while United States Natural Gas Fund trades at $11.14 (market cap $517.27M). The key difference: Novo Nordisk A/S is far larger — about 319.6× United States Natural Gas Fund's market cap, and Novo Nordisk A/S pays a 4.71% dividend while United States Natural Gas Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and United States Natural Gas Fund for 22 Days on average.
| NVO | UNG | |
|---|---|---|
Market Cap | $165.31B | $517.27M |
Volume | 11,432,838 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $63.98 | $16.90 |
52-Week Low | $35.29 | $9.63 |
Typical Hold Time | 116 Days | 22 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
UNG trades at $11.06, up 0.28% with a bullish technical signal from moving averages. The fund reported $65.15M net income for 2024 despite zero revenue, with strong total assets of $790.02M and minimal debt. Recent news highlights natural gas market volatility with record production and geopolitical tensions influencing energy prices.
The outlook is mixed: technical strength and clean balance sheet support stability, but zero revenue and negative cash flow (-$251.70M) pose fundamental risks. Investors face exposure to natural gas price swings and supply-demand imbalances, requiring careful monitoring of energy market developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
